Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Phase II Clinical Trial of Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prevention Following Myeloablative Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Omer Jamy, MD, Racquel Innis-Shelton, MD, Susan Bal, MDMBBS, Ravi K. Paluri, MD, Samina Karim, Joseph H. Chewning, MD, Donna Salzman, MD, Luciano J. Costa, MD PhD, Antonio Di Stasi, MD, Lawrence S. Lamb, Jr., PhD, Shin Mineishi, Ayman Saad, MD

Blood (2019) 134 (Supplement_1): 2003.

https://doi.org/10.1182/blood-2019-129536

Published: 2019

Journal Articles

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Luciano J. Costa, MD PhD, Saurabh Chhabra, MD, Kelly N. Godby, MD, Eva Medvedova, MD, Robert F. Cornell, MD MS, Aric C. Hall, MD, Rebecca W. Silbermann, MD, Racquel Innis-Shelton, MD, Binod Dhakal, MBBS, Diego DeIdiaquez, MD, Pamela Hardwick, RN, Yelak Biru, James L. Omel, MD, Parameswaran Hari, MBBS, MD, Natalie Scott Callander, MD

Blood (2019) 134 (Supplement_1): 860.

https://doi.org/10.1182/blood-2019-123170

Published: 2019

Journal Articles

Autologous Hematopoietic Progenitor Cells Mobilization with Combination of Pegfilgrastim and Plerixafor: Efficacy and Cost Assessment

Luciano J. Costa, MD PhD, Racquel Innis-Shelton, MD, Joscelyn Bowersock, MT, Ayman Saad, MD, Donna Salzman, MD, Antonio Di Stasi, MD, Nicole Watts, PharmD, Lawrence S. Lamb, Jr., PhD

Blood (2017) 130 (Supplement 1): 4708.

https://doi.org/10.1182/blood.V130.Suppl_1.4708.4708

Published: 2017

Journal Articles

Prospective Study of Cardiac Events during Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma

Blood (2017) 130 (Supplement 1): 1855.

https://doi.org/10.1182/blood.V130.Suppl_1.1855.1855

Published: 2017

Journal Articles

Runx2 Deficiency in Committed Osteoblasts Promotes Myeloma Cell Homing to and Progression in New Bone Sites

Xiaoxuan Xu, Juan Li, MD, Timothy Trotter, Pramod Gowda, Xiaoxiao Hao, Jacob Calahan, Racquel Innis-Shelton, MD, Amjad Javed, Yang Yang, MD

Blood (2017) 130 (Supplement 1): 126.

https://doi.org/10.1182/blood.V130.Suppl_1.126.126

Published: 2017

Journal Articles

Carfilzomib Plus High Dose Melphalan Conditioning Prior to Autologous Hematopoietic Cell Transplantation Followed By Carfilzomib Maintenance in Patients with Relapsed Multiple Myeloma

Luciano J. Costa, MD PhD, Heather Landau, MD, Saurabh Chhabra, MD, Parameswaran Hari, MD MRCP, MS, Donna Salzman, MD, Ayman Saad, MD, Racquel Innis-Shelton, MD, Mehdi Hamadani, MD, Roni Tamari, MD, Kelly N. Godby, MD, Vladimir Petrovic, Lisa Williams, RN, Evelyn Orlando, Pamela M Dixon, RN, Sergio A. Giralt, MD

Blood (2016) 128 (22): 4630.

https://doi.org/10.1182/blood.V128.22.4630.4630

Published: 2016

Journal Articles

Favorable Immune Reconstitution Profile after Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Omer Hassan Jamy, MD, Ayman Saad, MD, Rachael Orlandella, BS, Samantha B Langford, BS, Ravi K. Paluri, MD, Racquel Innis-Shelton, MD, Shin Mineishi, MD, Lawrence S. Lamb, Jr., PhD

Blood (2016) 128 (22): 2236.

https://doi.org/10.1182/blood.V128.22.2236.2236

Published: 2016

Journal Articles

Heparanase Promotes Myeloma Metastasis By Inducing EMT-like Features in Both Myeloma Cells and Endothelial Cells

Qianying Pan, MD, Patrick D Rowan, BS, Racquel Innis-Shelton, MD, Timothy N Trotter, BS, Mei Li, PhD, Deniz Peker, MD, Larry J Suva, PhD, Yang Yang, MD PhD

Blood (2014) 124 (21): 2025.

https://doi.org/10.1182/blood.V124.21.2025.2025

Published: 2014

Journal Articles

Immune Reconstitution and Chimerism in Allogeneic HSCT Patients Treated with Post-HSCT High Dose Cyclophosphamide As Prophylaxis Against GvHD

Paluri k Ravi, Samina Karim, Gretchen Cloud, Mary Lamb, Samantha Langford, Shin Mineishi, MD, Racquel-innis Shelton, Ayman Saad, MD, Donna Salzman, MD, Lawrence S. Lamb, PhD

Blood (2014) 124 (21): 2474.

https://doi.org/10.1182/blood.V124.21.2474.2474

Published: 2014

Journal Articles

Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience

Racquel Innis-Shelton, MD, Donna Salzman, MD, Antonio Di Stasi, MD, Lawrence S. Lamb, PhD, Melissa Gazi, Lisa Williams, RN, Luciano J Costa, MD PhD, Harry Erba, Shin Mineishi, MD, Ayman Saad, MD

Blood (2014) 124 (21): 3911.

https://doi.org/10.1182/blood.V124.21.3911.3911

Published: 2014

Journal Articles

Heparanase Expression Correlates with Bone Destruction in the Patients with Multiple Myeloma

Shi Wei, MD, Racquel Innis-Shelton, MD, Li Nan, Jian Ruan, MD, Rebecca S Sollie, Vishnu V B Reddy, MD, Yang Yang, MD, PhD

Blood (2012) 120 (21): 1813.

https://doi.org/10.1182/blood.V120.21.1813.1813

Published: 2012

NARROW

A Phase II Clinical Trial of Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prevention Following Myeloablative Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Autologous Hematopoietic Progenitor Cells Mobilization with Combination of Pegfilgrastim and Plerixafor: Efficacy and Cost Assessment

Prospective Study of Cardiac Events during Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma

Runx2 Deficiency in Committed Osteoblasts Promotes Myeloma Cell Homing to and Progression in New Bone Sites

Carfilzomib Plus High Dose Melphalan Conditioning Prior to Autologous Hematopoietic Cell Transplantation Followed By Carfilzomib Maintenance in Patients with Relapsed Multiple Myeloma

Favorable Immune Reconstitution Profile after Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Heparanase Promotes Myeloma Metastasis By Inducing EMT-like Features in Both Myeloma Cells and Endothelial Cells

Immune Reconstitution and Chimerism in Allogeneic HSCT Patients Treated with Post-HSCT High Dose Cyclophosphamide As Prophylaxis Against GvHD

Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience

Heparanase Expression Correlates with Bone Destruction in the Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only